Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif 94800, France.
Ann Oncol. 2012 Sep;23 Suppl 10:x309-12. doi: 10.1093/annonc/mds352.
The treatment of renal cell carcinoma has dramatically changed in the past 6 years with the approval of seven new drugs since 2006. although treatment algorithms have been reported and updated every year since 2006, the choice of targeted therapy is not always easy. Selecting a targeted agent in metastatic renal cell carcinoma (mRCC) should take into account various parameters, including the status of the disease, the histology, the status of the patient and finally the availability of the drugs in each country. In addition, in front of every patient, the physician will need to raise important questions such as whether the patient should be treated, should receive surgery, and also what is his prognostic group. The different options are described in this manuscript.
自 2006 年以来，已有七种新药获得批准，过去 6 年来，肾细胞癌的治疗发生了显著变化。尽管自 2006 年以来，每年都有治疗算法的报告和更新，但靶向治疗的选择并不总是那么容易。在转移性肾细胞癌（mRCC）中选择靶向药物时，应考虑多种参数，包括疾病状态、组织学、患者状况以及每个国家药物的可及性。此外，对于每一位患者，医生都需要提出一些重要问题，例如患者是否需要治疗、是否应接受手术，以及他的预后分组如何。本文描述了不同的选择。
